Article summary
The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated. Clinical development took longer than expected. Capital became scarce. Several companies downsized or disappeared altogether. Investors who entered during the first wave learned a lesson that every biotech investor eventually faces: scientific breakthroughs rarely follow market timelines. The post The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet appeared first on Microdose.
Continue to the original publication for the complete article.